FAQ on Clene's CNM-Au8 FDA Guidance and ALS Treatment Advancements
Summary
Clene Inc. has received FDA guidance to use data from its expanded access programs for an accelerated approval of CNM-Au8, a promising ALS treatment, with plans to submit additional data by mid-2025 and start a Phase 3 trial, highlighting its potential to significantly benefit ALS patients.
What is CNM-Au8 and what is its purpose?
CNM-Au8 is an investigational first-in-class therapy developed by Clene Inc. aimed at improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis.
Why is the FDA’s guidance on CNM-Au8 significant?
The FDA’s guidance allows Clene to leverage data from its ongoing expanded access programs to support an accelerated approval application for CNM-Au8, recommending the use of neurofilament light chain biomarker analyses to substantiate the drug’s efficacy, which could expedite its availability to ALS patients.
How does CNM-Au8 work?
CNM-Au8 improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress.
When does Clene plan to submit additional data for CNM-Au8?
Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 RESTORE-ALS trial.
What are the clinical findings presented at the FDA meeting regarding CNM-Au8?
Clinical findings highlighted CNM-Au8’s significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy.
Where can I find more information about Clene and CNM-Au8?
For more information, please visit www.Clene.com or view the full press release at https://ibn.fm/xFrwd.
Who is involved in the development of CNM-Au8?
Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine Inc., is developing CNM-Au8. The company is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases.
What should ALS patients know about CNM-Au8?
ALS patients should know that CNM-Au8 has shown significant survival benefits and a benign safety profile in clinical findings, with Clene committed to addressing the urgent unmet needs of ALS patients through its development.
How can investors stay updated on Clene’s progress?
Investors can stay updated by visiting the company’s newsroom at https://ibn.fm/CLNN or the InvestorBrandNetwork website at https://www.InvestorBrandNetwork.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 127058